Daria G. Husni

Daria G. Husni is Assistant Editor for BioPharm International.

Articles

FDA Grants Orphan Drug Designation to First-in-Class Treatment for Eosinophilic Esophagitis

The immune-resetting peptide, developed by Revolo Biotherapeutics, received positive results from its Phase IIb study.

Sanofi to Aquire Inhibrx for $1.7 Billion

The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.

Novartis Acquires Calypso Biotech for up to $425 Million

The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.

AstraZeneca to Acquire Icosavax in Deal Valued at Approximately $1.1 Billion

With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.

Autifony Signs $770.5 Million License and Collaboration with Jazz Pharmaceuticals

Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.

Update on Facilities and Manufacturing Trends

A look into the latest developments in biopharmaceutical manufacturing and facilities.

FDA Approves First Recombinant Treatment for Rare Blood Clotting Disorder

Adzynma provides a replacement for low levels of the ADAMTS13 enzyme in patients with congenital thrombotic thrombocytopenic purpura.

New Biologic Treatment for Hidradenitis Suppurativa Receives FDA Approval

This is the second biologic approved to treat HS, a painful and reoccurring skin disease.

FDA Approves Vaccine for Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

PENBRAYA combines components from two meningococcal vaccines, Trumenba and Nimenrix.

CPHI Barcelona: CMOs Expected to Account for 45% Available Bio Capacity in 2027

As CMOs continue to invest in cell culture capacity, some are expected to surpass top in-house companies.